News
BNTC
12.00
+5.08%
0.58
Weekly Report: what happened at BNTC last week (0406-0410)?
Weekly Report · 21h ago
Weekly Report: what happened at BNTC last week (0330-0403)?
Weekly Report · 04/06 10:05
Weekly Report: what happened at BNTC last week (0323-0327)?
Weekly Report · 03/30 10:05
Weekly Report: what happened at BNTC last week (0316-0320)?
Weekly Report · 03/23 10:01
Weekly Report: what happened at BNTC last week (0309-0313)?
Weekly Report · 03/16 10:02
Benitec To Highlight Key Clinical Results Observed To Date For OPMD Patients Enrolled Into BB-301 Phase 1b/2a Clinical Treatment Study And Potential For BB-301 To Transform Treatment Landscape For Patients With OPMD At 2026 MDA Clinical and Scientific Conference
Benzinga · 03/10 11:09
Benitec Biopharma to host MDA conference industry forum breakfast on BB-301 OPMD trial results
Reuters · 03/10 11:03
Benitec Biopharma publishes corporate presentation on BB-301 durability in oculopharyngeal muscular dystrophy dysphagia###
Reuters · 03/09 23:52
Benitec Biopharma Reports Promising Interim Results For BB-301 Gene Therapy In OPMD Trial
NASDAQ · 03/09 20:14
Benitec Biopharma Price Target Maintained With a $32.00/Share by HC Wainwright & Co.
Dow Jones · 03/09 16:30
HC Wainwright & Co. Reiterates Buy on Benitec Biopharma, Maintains $32 Price Target
Benzinga · 03/09 16:20
Reiterating Buy on Benitec: Promising Early BB-301 Data in OPMD Underpin $32 12‑Month Target
TipRanks · 03/09 14:45
Benitec Biopharma announces interim Phase 1b/2a study of BB-301
TipRanks · 03/09 11:15
BENITEC BIOPHARMA ANNOUNCES POSITIVE INTERIM PHASE 1B/2A RESULTS FOR HIGH DOSE BB-301 AND CONTINUED DURABLE IMPROVEMENTS FOR LOW DOSE BB-301 TREATMENT AT THE 2026 MUSCULAR DYSTROPHY ASSOCIATION CLINICAL & SCIENTIFIC CONFERENCE
Reuters · 03/09 11:00
Weekly Report: what happened at BNTC last week (0302-0306)?
Weekly Report · 03/09 10:02
Benitec Biopharma: Emerging BB-301 Clinical Profile and Upcoming Data Catalyst Support Buy Rating and $32 Target
TipRanks · 03/02 11:35
Weekly Report: what happened at BNTC last week (0223-0227)?
Weekly Report · 03/02 10:01
Benitec Biopharma BB-301 Phase 1b/2a Late-Breaking Abstract Accepted At 2026 Muscular Dystrophy Association Clinical And Scientific Conference
Benzinga · 02/23 12:06
Benitec Biopharma to Present BB-301 Phase 1b/2a Interim Data at Muscular Dystrophy Association Clinical and Scientific Conference
Reuters · 02/23 12:01
BENITEC BIOPHARMA ANNOUNCES ACCEPTANCE OF LATE- BREAKING ABSTRACT FOR THE BB-301 PHASE 1B/2A CLINICAL TREATMENT STUDY AT THE MUSCULAR DYSTROPHY ASSOCIATION CLINICAL & SCIENTIFIC CONFERENCE
Reuters · 02/23 12:00
More
Webull provides a variety of real-time BNTC stock news. You can receive the latest news about Benitec Biopharm through multiple platforms. This information may help you make smarter investment decisions.
About BNTC
Benitec Biopharma Inc is a clinical-stage biotechnology company. The Company is focused on the advancement of novel genetic medicines. Its proprietary Silence and Replace deoxyribonucleic acid (DNA) -directed ribonucleic acid (RNA) interference platform combines RNA interference, or RNAi, with gene therapy to create medicines that simultaneously facilitate sustained silencing of disease-causing genes and concomitant delivery of wildtype replacement genes following a single administration of the therapeutic construct. The Company is developing Silence and Replace-based therapeutics (BB-301) for chronic and life-threatening human conditions including Oculopharyngeal Muscular Dystrophy (OPMD). BB-301 is an adeno-associated viral vector (AAV)-based gene therapy designed to silence the expression of disease-causing genes (to slow, or halt, the underlying mechanism of disease progression) and to simultaneously replace the mutant genes with normal, wildtype genes.